Exact Sciences Corp (EXAS) concluded trading on Thursday at a closing price of $50.44, with 6.05 million shares of worth about $305.19 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.17% during that period and on January 16, 2025 the price saw a loss of about -5.75%. Currently the company’s common shares owned by public are about 185.05M shares, out of which, 182.42M shares are available for trading.
Stock saw a price change of -11.01% in past 5 days and over the past one month there was a price change of -17.65%. Year-to-date (YTD), EXAS shares are showing a performance of -10.23% which decreased to -23.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $40.62 but also hit the highest price of $79.62 during that period. The average intraday trading volume for Exact Sciences Corp shares is 2.49 million. The stock is currently trading -11.25% below its 20-day simple moving average (SMA20), while that difference is down -12.27% for SMA50 and it goes to -12.66% lower than SMA200.
Exact Sciences Corp (NASDAQ: EXAS) currently have 185.05M outstanding shares and institutions hold larger chunk of about 99.84% of that.
The stock has a current market capitalization of $9.34B and its 3Y-monthly beta is at 1.24. It has posted earnings per share of -$1.17 in the same period. It has Quick Ratio of 1.93 while making debt-to-equity ratio of 0.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EXAS, volatility over the week remained 7.84% while standing at 4.44% over the month.
Stock’s fiscal year EPS is expected to drop by -3.88% while it is estimated to increase by 79.18% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on August 28, 2024 offering an Overweight rating for the stock and assigned a target price of $75 to it. Coverage by Scotiabank stated Exact Sciences Corp (EXAS) stock as a Sector outperform in their note to investors on June 27, 2024, suggesting a price target of $70 for the stock. On June 03, 2024, Jefferies Resumed their recommendations, while on January 02, 2024, The Benchmark Company Upgrade their ratings for the stock with a price target of $91. Stock get a Buy rating from Guggenheim on December 14, 2023.
